SCHEMBL712172

SCHEMBL712172

Fc1ccc(CNCC2C3CNCC23)cc1OC1CCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.43
DUT P33316 1/20 0.42
SLC6A9 P48067 2/20 0.42
SLC6A5 Q9Y345 1/20 0.42
EPHX2 P34913 1/20 0.37
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
KCNH2 Q12809 1/20 0.35
CSNK2A1 P68400 2/20 0.34
SLC6A4 P31645 3/20 0.34
PDE4B Q07343 2/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
HTR1A P08908 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL709607 0.99 RECQL (0.42) RECQLDUTSLC6A9SLC6A5EPHX2
SCHEMBL3773454 0.80 MEN1 (0.35) KCNH2HTR2CMEN1KMT2ANPSR1
SCHEMBL712199 0.78 SSTR4 (0.40) HTR2CMEN1KMT2A
SCHEMBL712171 0.77 EPHX2 (0.53) SLC6A9SLC6A5EPHX2PDE4BPDE4A
SCHEMBL709606 0.76 EPHX2 (0.52) SLC6A9SLC6A5EPHX2PDE4BPDE4A
SCHEMBL15967241 0.76 PRMT5 (0.47) SLC6A9KCNH2SLC6A4MEN1KMT2A
Hydrochloric Acid SCHEMBL709865 0.75 PRMT5 (0.46) SLC6A9KCNH2SLC6A4KMT2ASLC6A2
SCHEMBL708327 0.74 P2RX7 (0.47) SLC6A9SLC6A5KCNH2SLC6A4
Hydrochloric Acid SCHEMBL711110 0.73 P2RX7 (0.47) SLC6A9SLC6A5KCNH2SLC6A4
SCHEMBL7360316 0.71 CSNK2A1 (0.44) RECQLDUTSLC6A9SLC6A5EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP claimed
EP-1869019-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS Pfizer Products Incorporated (US) 2007-12-26 EP claimed
WO-2006106425-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PRODUCTS INC. (US) 2006-10-12 WO claimed
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP disclosed
US-8124639-B2 Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. (US) 2012-02-28 US disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 RECQL 1041/4885DUT 4602/4885SLC6A9 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.